title: Inhalation therapy of calcitonin relieves osteoarthritis of the knee.
abstract: This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1β, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee osteoarthritis (OA) when used concomitantly with exercise therapy. Fifty female patients with knee OA were randomized into two groups. The first group (n = 30) received 200 IU/day nasal salmon calcitonin and a home exercise program; the second group (n = 20) received a home exercise program for 6 months. Compared with baseline,while significant improvements were observed in visual analogue scale (VAS), WOMAC pain, physical function scores, 20-m walking time (P < 0.001) and WOMAC stiffness score (P = 0.041) in the first group, walking and resting VAS, and WOMAC physical function scores were improved (P = 0.029) in the second group after treatment. Significantly increased levels of serum NO and urinary CTX-II (P < 0.001) and significant improvements in the area of medial femoral condyle (P < 0.05) were noted only in the first group. There were significant differences in VAS activation values (P = 0.032) and NO levels (P < 0.001) in the favor of the first group. In conclusion, nasal salmon calcitonin may have possible chondroprotective effects besides its known effects on symptoms in patients with knee OA.
authors.affiliation: Department of Physical Therapy and Rehabilitation, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey. dronurarmagan@hotmail.com
authors.forename: Onur
authors.initials: O
authors.lastname: Armagan
authors.forename: Dilek Kaya
authors.initials: DK
authors.lastname: Serin
authors.forename: Cüneyt
authors.initials: C
authors.lastname: Calisir
authors.forename: Ali
authors.initials: A
authors.lastname: Dokumacioglu
authors.forename: Merih
authors.initials: M
authors.lastname: Ozgen
authors.forename: Setenay
authors.initials: S
authors.lastname: Oner
authors.forename: Ozkan
authors.initials: O
authors.lastname: Alatas
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use*; D024043:Collagen Type II / Q000652:urine; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood; D008279:Magnetic Resonance Imaging; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood; D020370:Osteoarthritis, Knee / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010446:Peptide Fragments / Q000652:urine; D011859:Radiography; D012138:Respiratory Therapy; D012720:Severity of Illness Index; D016896:Treatment Outcome; D016138:Walking
chemical_list: D050071:Bone Density Conservation Agents; D024043:Collagen Type II; D053583:Interleukin-1beta; D010446:Peptide Fragments; C543437:collagen II C-telopeptide; D009569:Nitric Oxide; C028815:salmon calcitonin; D002116:Calcitonin; D019278:Matrix Metalloproteinase 3